The molecular genetics of prostate cancer

Urology

Volumn 62, Issue 5 SUPPL. 1, 2003, Pages 3-10

  Visakorpi, Tapio ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BLOOD CLOTTING FACTOR 6; COMPLEMENTARY DNA; GLUTATHIONE TRANSFERASE; INITIATION FACTOR; LIGAND; PROTEIN TYROSINE PHOSPHATASE; UVOMORULIN;

CANCER GENETICS; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME; DNA MICROARRAY; DNA SEQUENCE; EUKARYOTE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE TARGETING; INHERITANCE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0242523099     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00776-3     Document Type: Article

References (37)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1999. CA Cancer J Clin. 49:1999;8-31.
2. Elo J.P., Visakorpi T. Molecular genetics of prostate cancer. Ann Med. 33:2001;130-141.
3. Visakorpi T. Molecular genetics of prostate cancer. Ann Chir Gynaecol. 88:1999;11-16.
4. Berry R., Schaid D.J., Smith J.R., et al. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet. 66:2000;539-546.
5. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 274:1996;1371-1374.
6. Berthon P., Valeri A., Cohen-Akenine A., et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet. 62:1998;1416-1424.
7. Gibbs M., Stanford J.L., McIndoe R.A., et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet. 64:1999;776-787.
8. Suarez B.K., Lin J., Burmester J.K., et al. A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet. 66:2000;933-944.
9. Tavtigian S.V., Simard J., Teng D.H.F., et al. A candidate prostate cancer susceptibility gene at chromosome 17 p. Nat Genet. 27:2001;172-180.
10. Berry R., Schroeder J.J., French A.J., et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet. 67:2000;82-91.
11. Xu J., Meyers D., Frieje D., et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 20:1998;175-179.
12. Wang L., McDonnell S.K., Elkins D.A., et al. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 61:2001;6494-6495.
13. Simard J., Dumont M., Soucy P., et al. Perspective prostate cancer susceptibility genes . Endocrinology. 143:2002;2029-2040.
14. Wu Y.Q., Chen H., Rubin M.A., et al. Loss of heterozygosity of the putative prostate cancer susceptibility gene HPC2/ELAC2 is uncommon in sporadic and familial prostate cancer. Cancer Res. 61:2001;8651-8653.
15. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 30:2002;181-184.
16. Rökman A., Ikonen T., Seppälä E.H., et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet. 70:2002;1299-1304.
17. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer analyses of cohorts of twins from Sweden, Denmark, and Finland . N Engl J Med. 343:2000;78-85.
18. Visakorpi T., Kallioniemi A.H., Syvanen A.C., et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55:1995;342-347.
19. Nupponen N.N., Kakkola L., Koivisto P., et al. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol. 153:1998;141-148.
20. De Marzo A.M., Marchi V.L., Epstein J.I., et al. Proliferative inflammatory atrophy of the prostate implications for prostatic carcinogenesis . Am J Pathol. 155:1999;1985-1992.
21. Brooks J.D., Weinstein M., Lin X., et al. CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 7:1998;531-536.
22. Kwabi-Addo B., Giri D., Schmidt K., et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A. 98:2001;11563-11568.
23. Narla G., Heath K.E., Reeves H.L., et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 294:2001;2563-2566.
24. Umbas R., Schalken J.A., Aalders T.W., et al. Expression of the cellular adhesion molecule e-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52:1992;5104-5109.
25. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13:1999;966-977.
26. Nupponen N.N., Porkka K., Kakkola L., et al. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol. 154:1999;1777-1783.
27. Saramaki O., Willi N., Bratt O., et al. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol. 159:2001;2089-2094.
28. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput profiling of tumor specimens. Nat Med. 4:1998;844-877.
29. Duggan D.J., Bittner M., Chen Y., et al. Expression profiling using cDNA microarrays. Nat Genet. 21:(suppl):1999;10-14.
30. Porkka K., Saramaki O., Tanner M., et al. Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. Lab Invest. 82:2002;629-637.
31. Palmberg C., Koivisto P., Kakkola L., et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol. 164:2000;1992-1995.
32. Linja M.J., Savinainen K.J., Saramäki O.R., et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61:2001;3550-3555.
33. Visakorpi T. New pieces to the prostate cancer puzzle. Nat Med. 5:1999;264-265.
34. Craft N., Shostak Y., Carey M., et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 5:1999;280-285.
35. Visakorpi T., Kallioniemi O.-P., Koivula T., et al. Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol. 5:1992;643-648.
36. Enattah N., Sahi T., Savilahti E., et al. Identification of a variant associated with adult-type hypolactasia. Nat Genet. 30:2002;233-237.
37. Pagani F., Buratti E., Stuani C., et al. A new type of mutation causes a splicing defect in ATM. Nat Genet. 30:2002;426-429.